Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Cvitkovic
E
E
Marty
M
M
Wasserman
E
E
Cuvier
C
C
Goldwasser
F
F
Misset
J L
JL
D015746:Abdominal Pain / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives; D002799:Cholinergic Fibers / Q000187:drug effects*; D006801:Humans; D000077146:Irinotecan; D009944:Organoplatinum Compounds / Q000009:adverse effects; D000077150:Oxaliplatin; D010277:Parasympathomimetics / Q000009:adverse effects; D011950:Receptors, Cholinergic / Q000187:drug effects*; D013577:Syndrome
D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D010277:Parasympathomimetics; D011950:Receptors, Cholinergic; D000077150:Oxaliplatin; D000077146:Irinotecan; D002166:Camptothecin